PMID: 75395Feb 18, 1978Paper

Association between treatment-resistant kidney-allograft rejection and post-transplant appearance of antibodies to donor B-lymphocyte alloantigens

Lancet
J P SoulillouJ Guenel

Abstract

In 18 kidney-allograft recipients the post-transplant appearance of antibodies to B-lymphocyte (DRw) alloantigens of the kidney donor was significantly associated with the rejection of the graft within 1 month of transplantation or the poor recovery of graft function, despite treatment for rejection. None of the 10 recipients whose grafts were accepted or whose renal function recovered well after treatment for rejection made antibodies to donor B-lymphocyte antigens after transplantation. DRw antigens are thus targets for the host's immune response to a graft and may be responsible for kidney rejection in patients who do not respond to rejection therapy.

Citations

Jan 1, 1993·Transplant Immunology·D Talbot
Nov 25, 1978·Lancet·D AlbrechtsenE Thorsby
Nov 8, 1979·The New England Journal of Medicine·R D Guttmann
Apr 10, 1980·The New England Journal of Medicine·R J DuquesnoyH M Kauffman
Jun 3, 2017·Expert Review of Molecular Diagnostics·Lola JacquemontNicolas Degauque
May 1, 2006·Expert Review of Clinical Immunology·Caroline BalletJean-Paul Soulillou
Nov 28, 1997·The Journal of Laryngology and Otology·D BhargavaA S Daar
Feb 20, 2009·Acta Anaesthesiologica Scandinavica·A Barklin
Jun 2, 2018·Pediatric Transplantation·Gilad HamdaniAlin L Girnita
Jun 5, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Paul I Terasaki
Nov 8, 2016·Transplantation·Jean-Paul Soulillou
Apr 1, 1983·Tissue Antigens·A YthierJ P Soulillou
Jul 1, 1980·Tissue Antigens·J D BignonJ Guenel
Sep 1, 1984·Annales d'immunologie·P de FaucalJ P Soulillou
Aug 1, 1979·Kidney International·C D HongJ W Alexander

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.